Vol 3: A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation.Reportar como inadecuado



 Vol 3: A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation.


Vol 3: A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation. - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Descargar gratis o leer online en formato PDF el libro: Vol 3: A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation.
This article is from Transplantation Research, volume 3.AbstractBackground: The purpose of this study was to test the efficacy and safety of daclizumab (DZM) versus anti-thymocyte globulin (ATG) as a component of induction therapy in heart transplant recipients. Methods: Thirty heart transplant patients were randomized to receive either ATG or DZM

Autor: Mullen, John C; Kuurstra, Emily J; Oreopoulos, Antigone; Bentley, Michael J; Wang, Shaohua

Fuente: https://archive.org/







Documentos relacionados